IPO
Resverlogix Corp. announces a warrant exercise incentive program designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company.
Indus Holdings, Inc. announced that it has changed the date of its previously announced earnings release and earnings call.
Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the closing of its previously announced offering.
The Board of Directors resolved on a rights issue of 75 MSEK, guaranteed to 80 percent, where the subscription period is ongoing
Philadelphia, PA – Oncoceutics, Inc. announced that new data will be presented on the efficacy and mechanism of action of imipridones ONC201 and ONC206 at the 24th Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona.
Crohn’s & Colitis Foundation’s IBD Ventures award supports development of Thetis’ novel first-in-class Resolvin oral therapy (TP-317) for treatment of ulcerative colitis and Crohn’s disease
Series A round lead investors NordicNinja and Industrifonden to support Combinostics as they scale to US and Asia
Vivoryon Therapeutics AG, will publish its third quarter financial results and a business update for the period ended September 30, 2019 on Thursday, November 28, 2019, in the form of an interim management report.
Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, announced the establishment of an equity line facility to enhance the Company’s financial flexibility and improve liquidity for shareholders.
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
PRESS RELEASES